Northern Trust
GEVA

Northern Trust’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Northern Trust’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-266,963
Closed -$26M – 4329
2015
Q1 		$26M Buy
266,963
+33,879
+15% +$3.59M 0.01% 1367
2014
Q4 		$21.6M Sell
233,084
-8,392
-3% -$662K 0.01% 1481
2014
Q3 		$16.6M Sell
241,476
-10,663
-4% -$764K 0.01% 1648
2014
Q2 		$26.4M Sell
252,139
-4,206
-2% -$358K 0.01% 1291
2014
Q1 		$21.3M Sell
256,345
-16,011
-6% -$1.48M 0.01% 1526
2013
Q4 		$17.6M Buy
272,356
+21,841
+9% +$1.3M 0.01% 1630
2013
Q3 		$15.9M Buy
250,515
+60,117
+32% +$2.96M 0.01% 1648
2013
Q2 		$7.99M Buy
+190,398
New +$8.68M ﹤0.01% 2090

Northern Trust's GEVA Position: Q2 2015 in Review

Northern Trust sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 266,963 shares — an estimated $26M sold.

Northern Trust first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $26.4M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Northern Trust reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Northern Trust sold 266,963 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $26M.
  • Northern Trust first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Northern Trust's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $26.4M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Northern Trust's 13F filing for Q2 2015, filed 13 Aug 2015.